Drugs /

nemvaleukin alfa

Back to Drugs List

Overview

NCI Definition [1]:
A selective effector cell activator protein and agonist of the intermediate-affinity interleukin-2 (IL-2) receptor with potential immunostimulating and antineoplastic activity. Upon administration, intermediate-affinity interleukin-2 receptor agonist ALKS 4230 binds to and signals through the intermediate-affinity IL-2 receptor complex; this may selectively stimulate and activate natural killer (NK) cells and memory CD8 T-cells, leading to tumor cell elimination, while circumventing the activation of immunosuppressive cells that may prevent the anti-tumor response. IL-2 is a cytokine signaling molecule that plays a critical role in the immune response.

Clinical Trials

View Clinical Trials for nemvaleukin alfa

Nemvaleukin alfa has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating nemvaleukin alfa, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open).

Deficient DNA Mismatch Repair (dMMR), ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for nemvaleukin alfa clinical trials.

Malignant solid tumor, cutaneous melanoma, and renal cell carcinoma are the most common diseases being investigated in nemvaleukin alfa clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Nemvaleukin Alfa
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating nemvaleukin alfa and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
intermediate-affinity il-2r agonist alks 4230, intermediate-affinity il-2r agonist alks 4230, rdb 1450, alks 4230, intermediate-affinity interleukin-2 receptor agonist alks 4230, rdb-1450
Drug Target(s) [2]:
IL2RB, IL2RG
NCIT ID [1]:
C128107

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.